Changes in Cardiac and Vascular Haemodynamics as Potential Mediators of Cardiovascular and Kidney Outcomes With Empagliflozin in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
J Diabetes Complicat 2023 Aug 17;37(9)108588, BK Krämer, SJ Hauske, R Chilton, JFE Mann, L Gullestad, D Fitchett, M Mattheus, D Steubl, C WannerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.